The methodology used to formulate this article included reviewing published reports from various databases (from inception to 03 June 2024, without language restrictions): Scopus, PubMed, Google Scholar, ISI Web of Science, and CNKI to maximise the retrieval of relevant results
doi: 10.1017/cts.2023.612
These bacteria are known for their roles in SCFA production, which can stimulate GLP-1 and PYY release, supporting appetite regulation and weight loss
Cost and insurance-related barriers are the most common reasons people stop taking GLP-1s, according to research by Gasoyan's team
That reliability standard is the same everywhere because it is anchored in patient risk, not in location
GLP-1R agonism slows gastric emptying, suppresses appetite via hypothalamic and brainstem pathways, and augments glucose-dependent insulin secretion [1]